Humana Inc. $HUM Shares Acquired by Illinois Municipal Retirement Fund

Illinois Municipal Retirement Fund boosted its stake in Humana Inc. (NYSE:HUM) by 3.8% during the 3rd quarter, HoldingsChannel.com reports. The fund owned 64,639 shares of the insurance provider’s stock after purchasing an additional 2,364 shares during the period. Illinois Municipal Retirement Fund’s holdings in Humana were worth $24,664,000 as of its most recent filing with the SEC.

A number of other hedge funds and other institutional investors have also recently added to or reduced their stakes in the stock. BlackRock Inc. purchased a new stake in Humana in the second quarter worth $4,138,160,000. Pzena Investment Management LLC purchased a new position in shares of Humana during the 2nd quarter valued at $1,749,014,000. Assenagon Asset Management S.A. lifted its position in shares of Humana by 20,126.8% during the 3rd quarter. Assenagon Asset Management S.A. now owns 1,255,479 shares of the insurance provider’s stock valued at $479,053,000 after buying an additional 1,249,272 shares during the last quarter. Legal & General Group Plc purchased a new position in shares of Humana during the 2nd quarter valued at $329,760,000. Finally, Barrow Hanley Mewhinney & Strauss LLC purchased a new position in shares of Humana during the 2nd quarter valued at $314,922,000. 92.38% of the stock is currently owned by hedge funds and other institutional investors.

Analyst Upgrades and Downgrades

Several brokerages recently weighed in on HUM. Lake Street Capital initiated coverage on Humana in a report on Thursday, July 30th. They issued a “buy” rating for the company. Wall Street Zen raised shares of Humana from a “hold” rating to a “buy” rating in a report on Monday. HSBC lowered shares of Humana to a “hold” rating in a research report on Thursday, July 30th. Leerink Partners upgraded shares of Humana from a “market perform” rating to an “outperform” rating and set a $513.00 target price for the company in a research report on Thursday, July 30th. Finally, JPMorgan Chase & Co. lifted their target price on shares of Humana from $393.00 to $484.00 and gave the stock a “neutral” rating in a research note on Tuesday. Twenty-one equities research analysts have rated the stock with a Buy rating, ten have given a Hold rating and one has given a Sell rating to the company’s stock. According to data from MarketBeat, the company presently has an average rating of “Moderate Buy” and an average target price of $469.57.

Humana Price Performance

Humana stock opened at $437.69 on Wednesday. Humana Inc. has a one year low of $163.11 and a one year high of $456.50. The business has a fifty day moving average price of $405.76 and a 200-day moving average price of $313.90. The company has a debt-to-equity ratio of 0.61, a current ratio of 1.65 and a quick ratio of 1.74. The firm has a market capitalization of $52.56 billion, a P/E ratio of 42.58, a PEG ratio of 2.46 and a beta of 0.65.

Humana (NYSE:HUM) last released its quarterly earnings data on Friday, November 6th. The insurance provider reported ($0.70) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($1.00) by $0.30. The company had revenue of $41.16 billion for the quarter, compared to analyst estimates of $40.87 billion. Humana had a return on equity of 8.50% and a net margin of 0.81%. The firm’s revenue for the quarter was up 26.1% compared to the same quarter last year. During the same period in the previous year, the company posted $3.24 EPS. Humana has set its FY 2026 guidance at 9.500- EPS. As a group, equities research analysts forecast that Humana Inc. will post 9.57 EPS for the current year.

Humana Dividend Announcement

The business also recently announced a quarterly dividend, which will be paid on Friday, January 29th. Shareholders of record on Thursday, December 24th will be issued a dividend of $0.8850 per share. This represents a $3.54 dividend on an annualized basis and a yield of 0.8%. The ex-dividend date of this dividend is Thursday, December 24th. Humana’s payout ratio is presently 34.44%.

More Humana News

Here are the key news stories impacting Humana this week:

• Positive Sentiment: Humana’s raised 2026 adjusted EPS outlook—to at least $9.50 from at least $9.00—helped sustain optimism after third-quarter results beat expectations for a smaller loss and higher revenue. Its 93.7% insurance benefit ratio was also favorable to prior guidance. Why Is Humana Stock Trading Higher Tuesday?
• Positive Sentiment: Humana, Evolent and American Oncology Network introduced an oncology care model intended to eliminate prior-authorization requirements for participating cancer care. The change may reduce administrative burden, though its financial impact was not specified. New oncology model from Humana, Evolent and American Oncology Network
• Positive Sentiment: Analysts raised price targets following the results, adding support to the bullish outlook. Recent examples include Guggenheim at $521, Barclays at $587 and JPMorgan at $484, though JPMorgan maintained a neutral rating. Humana Analysts Raise Their Forecasts After Q3 Results
• Neutral Sentiment: Humana launched cash tender offers for eight series of senior notes, with an aggregate purchase cap of $1.5 billion. The move represents active debt management, but the announcement does not establish a direct earnings benefit. Humana Commences Offers to Purchase Certain Debt Securities

Humana Profile

Humana Inc. is a U.S. health and wellness company that provides health insurance and healthcare services. Its insurance offerings include Medicare Advantage, Medicare Supplement and prescription drug plans, as well as Medicaid and employer-sponsored plans. The company also provides care through CenterWell, its healthcare services brand, which includes primary care, home health and pharmacy services. Its insurance and care offerings are available in markets across the United States, with availability varying by product and location.